{"id":47096,"date":"2022-08-09T16:01:57","date_gmt":"2022-08-09T14:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/"},"modified":"2022-08-09T16:01:57","modified_gmt":"2022-08-09T14:01:57","slug":"synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/","title":{"rendered":"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test"},"content":{"rendered":"
\n

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx<\/a> (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce the opening of a new, high-tech lab at the North Bethesda, MD Greencourt Innovation Center<\/a> (GIC) for the national launch of DISCERN\u2122<\/a>, a minimally invasive diagnostic test to identify AD in people living with dementia. DISCERN assesses the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD, as well as regulators of amyloid plaque and tau formation\u2014hallmarks of AD at autopsy.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nMartin Rosendale, CEO, Maryland Tech Council, says, \u201cIncredible innovations in life science and biotechnology are happening in Maryland and the DISCERN test is one of them. GIC is an advanced lab with the latest technology available and will serve as a great environment for the important work SDx technicians are performing to identify this devastating disease.\u201d\n<\/p>\n

\nThe test demonstrates >95% sensitivity and specificity, even in people recently diagnosed with dementia and is likely to reduce the number of people undergoing costly and often unreliable PET scans and invasive spinal fluid tests. DISCERN<\/a> combines three biomarkers: Morphometric Imaging to measure fibroblasts\u2019 ability to form networks; Protein Kinase C \u03b5 that correlates with synaptic activity; and AD-Index to measure phosphorylation of Erk1 and Erk2 in response to bradykinin.\n<\/p>\n

\n\u201cThe test results are available in a matter of weeks to inform the clinician\u2019s diagnosis and the most appropriate intervention for the patient, spanning medication, a clinical pathway or recommendations regarding diet, physical activity and mental exercise,\u201d says Frank Amato, CEO and president, SDx. \u201cWe\u2019re excited to locate our research and commercialization operations in GIC, which has been meticulously designed for companies like ours that are innovating at a high level.\u201d\n<\/p>\n

\nSDx will continue to build and scale its commercialization activities, providing prescribers, payers and patients with a diagnostic test that is an important breakthrough for the AD community.\n<\/p>\n

\nAbout SYNAPS Dx
\n
<\/b>SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD). The Company offers DISCERN\u2122, the first highly accurate, minimally invasive test supporting a clinician\u2019s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. SYNAPS Dx\u2019s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients seeking more information can visit https:\/\/discerntest.com\/<\/a>. For more information on the Company, visit https:\/\/www.synapsdx.com\/<\/a>. Contact: info@synapsdx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/b>
Caroline Chambers
\n
CPR Communications
\n
cchambers@cpronline.com<\/a>
201.641.1911 x 21\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce the opening of a new, high-tech lab at the North Bethesda, MD Greencourt Innovation Center (GIC) for the national launch of DISCERN\u2122, a minimally invasive diagnostic test … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47096","6":"format-standard","7":"category-industry"},"yoast_head":"\nSYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce the opening of a new, high-tech lab at the North Bethesda, MD Greencourt Innovation Center (GIC) for the national launch of DISCERN\u2122, a minimally invasive diagnostic test ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-09T14:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220809005028\/en\/1536668\/21\/lab.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test\",\"datePublished\":\"2022-08-09T14:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/\"},\"wordCount\":469,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220809005028\\\/en\\\/1536668\\\/21\\\/lab.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/\",\"name\":\"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220809005028\\\/en\\\/1536668\\\/21\\\/lab.jpg\",\"datePublished\":\"2022-08-09T14:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220809005028\\\/en\\\/1536668\\\/21\\\/lab.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220809005028\\\/en\\\/1536668\\\/21\\\/lab.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/","og_locale":"en_US","og_type":"article","og_title":"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test - Pharma Trend","og_description":"ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer\u2019s disease (AD), is pleased to announce the opening of a new, high-tech lab at the North Bethesda, MD Greencourt Innovation Center (GIC) for the national launch of DISCERN\u2122, a minimally invasive diagnostic test ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-09T14:01:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220809005028\/en\/1536668\/21\/lab.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test","datePublished":"2022-08-09T14:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/"},"wordCount":469,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220809005028\/en\/1536668\/21\/lab.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/","url":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/","name":"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220809005028\/en\/1536668\/21\/lab.jpg","datePublished":"2022-08-09T14:01:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220809005028\/en\/1536668\/21\/lab.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220809005028\/en\/1536668\/21\/lab.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/synaps-dx-opens-high-tech-laboratory-supporting-research-commercialization-of-discern-highly-accurate-minimally-invasive-alzheimers-disease-diagnostic-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer\u2019s Disease Diagnostic Test"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47096"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47096\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}